|
|
|
|
|
| Pharmacokinetics of Mequindox and Its Metabolites in Swine |
| LIU Yi-ming, LIU Ying-chun, DING Huan-zhong, FANG Bing-hu, YANG Fan, SHAN Qi , ZENGZhen-ling |
1. Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510640, P.R.China
2. Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200232, P.R.China |
|
|
|
摘要 The present study was carried out to investigate the pharmacokinetics of mequindox (MEQ), a new synthetic quinoxaline 1,4-dioxide derivative and its two main metabolites M1 [2-isoethanol mequinoox], M2 [2-isoethanol 1-desoxymequindox] in healthy swine. MEQ (10 mg kg-1 body weight) was administered to nine healthy cross-bread swine via oral, intramuscular, and intravenous routes in a randomized 3×3 crossover design with a 1-wk washout period. A sensitive high-performance liquid chromatography (HPLC) method was used for the determination of plasma concentrations of MEQ and its metabolites M1 and M2. Plasma concentration versus time profiles of MEQ and its metabolites, M1 and M2, were analyzed by noncompartmental analysis using WinNonlin 5.2 software. The mean maximum concentrations (Cmax) of M1 and M2 after intravenous administration of MEQ were (5.27±1.59) μg mL-1 at 1.78 h and (1.01±0.29) μg mL-1 at 0.92 h, respectively. The mean maximum concentrations (Cmax) of MEQ, M1, and M2 were found to be (6.96±3.23), (6.61±1.56), and (0.78 ±0.25) μg mL-1, respectively at 0.15, 1.61, and 1.30 h after intramuscular administration of MEQ, respectively and (0.75±0.45), (6.90±1.52), and (0.62±0.21) μg mL-1, respectively at 0.40, 1.57, and 2.00 h, respectively after oral administration of MEQ. The apparent elimination half-lives (t1/2) of MEQ, M1, and M2 were (0.84±0.35), (7.57±3.93), and (9.56±6.00) h, respectively after intravenous administration of MEQ; (0.50±0.25), (6.30±3.00), and (5.94±2.54) h, respectively after intramuscular administration of MEQ; and (1.64±1.17), (5.59±1.93), and (16.25±10.27) h , respectively after oral administration of MEQ. The mean areas under the plasma concentration-time curve (AUC0- ) of MEQ, M1, and M2 were (4.88±1.54), (36.93±17.50), and (5.16±1.94) μg h mL-1, respectively after intravenous administration of MEQ; (4.18±0.76), (48.25±20.82), and (4.88±2.21) μg h mL-1 , respectively after intramuscular administration of MEQ; and (1.01±0.40), (48.83±20.71), and (5.54±2.23) μg h mL-1, respectively after oral administration of MEQ. MEQ was rapidly absorbed and metabolized in swine after oral, intramuscular, and intravenous administration. Further studies are required to investigate the double-peak phenomenon observed in the plasma concentration-time profile after oral administration and the pharmacokinetics of other metabolites of MEQ.
Abstract The present study was carried out to investigate the pharmacokinetics of mequindox (MEQ), a new synthetic quinoxaline 1,4-dioxide derivative and its two main metabolites M1 [2-isoethanol mequinoox], M2 [2-isoethanol 1-desoxymequindox] in healthy swine. MEQ (10 mg kg-1 body weight) was administered to nine healthy cross-bread swine via oral, intramuscular, and intravenous routes in a randomized 3×3 crossover design with a 1-wk washout period. A sensitive high-performance liquid chromatography (HPLC) method was used for the determination of plasma concentrations of MEQ and its metabolites M1 and M2. Plasma concentration versus time profiles of MEQ and its metabolites, M1 and M2, were analyzed by noncompartmental analysis using WinNonlin 5.2 software. The mean maximum concentrations (Cmax) of M1 and M2 after intravenous administration of MEQ were (5.27±1.59) μg mL-1 at 1.78 h and (1.01±0.29) μg mL-1 at 0.92 h, respectively. The mean maximum concentrations (Cmax) of MEQ, M1, and M2 were found to be (6.96±3.23), (6.61±1.56), and (0.78 ±0.25) μg mL-1, respectively at 0.15, 1.61, and 1.30 h after intramuscular administration of MEQ, respectively and (0.75±0.45), (6.90±1.52), and (0.62±0.21) μg mL-1, respectively at 0.40, 1.57, and 2.00 h, respectively after oral administration of MEQ. The apparent elimination half-lives (t1/2) of MEQ, M1, and M2 were (0.84±0.35), (7.57±3.93), and (9.56±6.00) h, respectively after intravenous administration of MEQ; (0.50±0.25), (6.30±3.00), and (5.94±2.54) h, respectively after intramuscular administration of MEQ; and (1.64±1.17), (5.59±1.93), and (16.25±10.27) h , respectively after oral administration of MEQ. The mean areas under the plasma concentration-time curve (AUC0- ) of MEQ, M1, and M2 were (4.88±1.54), (36.93±17.50), and (5.16±1.94) μg h mL-1, respectively after intravenous administration of MEQ; (4.18±0.76), (48.25±20.82), and (4.88±2.21) μg h mL-1 , respectively after intramuscular administration of MEQ; and (1.01±0.40), (48.83±20.71), and (5.54±2.23) μg h mL-1, respectively after oral administration of MEQ. MEQ was rapidly absorbed and metabolized in swine after oral, intramuscular, and intravenous administration. Further studies are required to investigate the double-peak phenomenon observed in the plasma concentration-time profile after oral administration and the pharmacokinetics of other metabolites of MEQ.
|
|
Received: 22 October 2010
Accepted:
|
| Fund: This study was supported by the National Basic Research Program of China (973 Program, 2009CB118805) and the National Key Technology Research and Development Program of China during the 10th Five-Year Plan Period (2009BADB7B05-03). |
|
Corresponding Authors:
Correspondence ZENG Zhen-ling, Mobile: 13609768425, E-mail: zlzeng@scau.edu.cn
E-mail: zlzeng@scau.edu.cn
|
| About author: LIU Yi-ming, Mobile: 13718937129, E-mail: liuyiming@caas.net.cn |
Cite this article:
LIU Yi-ming, LIU Ying-chun, DING Huan-zhong, FANG Bing-hu, YANG Fan, SHAN Qi , ZENGZhen-ling .
2011.
Pharmacokinetics of Mequindox and Its Metabolites in Swine. Journal of Integrative Agriculture, 10(12): 1968-1976.
|
| [1]Benet L Z, Galeazzi R L. 1979. Noncompartmental determination of the steady-state volume of distribution. Journal of Pharmaceutical Sciences, 68, 1071-1074. [2]Canga A G , Prieto A M S, Liebana M J D, Martinez N F, Vega M S, Vieitez J J G. 2009. The pharmacokinetics and metabolism of ivermectin in domestic animal species. The Veterinary Journal, 179, 25-37. [3]Chen Q, Tang S, Jin X, Zou J, Chen K, Zhang T, Xiao X. 2009. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food and Chemical Toxicology, 47, 328-334. [4]Chen Z L. 2002. Veterinary Pharmacology. 2nd ed. China Agrlculture Press, Beijing. p. 240. (in Chinese) Cutler D J. 1978. Theory of the absorption time, an adjunct to conventional bioavailability studies. Journal of Pharmacy and Pharmacology, 30, 476-478. [5]Du Z M, Yang L Z, Li S Z, Wang H Z, Bie C Q, Liu Y Q. 2008. Diagnosis and treatment of mequindox posining in chickens. Journal of Animal Science and Veterinary Medicine, 27, 118, 120. (in Chinese) Gibaldi M, Perrier D, 1982. Pharmacokinetics. 2nd ed. Marrcel Dekker, New York. pp. 409-417. [6]Huang X J, Ihsan A, Wang X, Dai M H, Wang Y L, Su S J, Xue X J, Yuan Z H. 2009. Long-term dose-dependent response of Mequindox on aldosterone, corticosterone and five steroidogenic enzyme mRNAs in the adrenal of male rats. Toxicology Letters, 191, 167-173. [7]Huang X J, Wang X, Ihsan A, Liu Q, Xue X J, Su S J, Yang C H, Zhou W, Yuan Z H. 2010. Interactions of NADPH oxidase, renin-angiotensin-aldosterone system and reactive oxygen species in mequindox-mediated aldosterone secretion in Wistar rats. Toxicology Letters, 198, 112-118. [8]Huang Y Q, Li Y Q, Yang Y J, Miao X L, Xie Y, Bai D Y, Lu C W, Sun L, Ma B Z. 2008. Studies on the pharmacokinetics of Mequindox in sheep. Journal of Northwest A&F University (Natural Science Edition), 36, 77-81. (in Chinese) [9]Kimura T, Higaki K. 2002. Gastrointestinal transit and drug absorption. Biological and Pharmaceutical Bulletin, 25, 149- 164. Knauf H, Mutschler E. 1995. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. Journal of Cardiovascular Pharmacology, 26, 394-400. [10]Lappin G, Rowland M, Garner R C. 2006. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opinion on Drug Metabolism & Toxicology, 2, 419-427. [11]Liu Y C, Si H B, He L M, Ding H Z, Huang X H, Chen J X, Chen Z L, Zeng Z L. 2010. Identification of mequindox and Its metabolites by high performance liquid chromatography combined with ion trap-time of flight-mass spectrometry. Chinese Journal of Analytical Chemistry, 10, 82-86. (in Chinese) [12]Liu Z Y, Huang L L, Chen D M, YUAN Z H. 2010. Metabolism of mequindox in liver microsomes of rats, chicken and pigs. Rapid Communications in Mass Spectrometry, 24, 909-918. [13]Lu C W, Li Y Q, Guan Y J, Zhang Y B, Bai D Y, Miao X L, Xiong Y J 2008. Pharmacokinetics of maquindox in rabbits with experimental hepatic injury. Journal of Northwest A&F University (Natural Science Edition), 36, 29-34. (in Chinese) [14]Mirfazaelian A, Mahmoudian M. 2006. A simple pharmacokinetics subroutine for modeling double peak phenomenon. Biopharmaceutics & Drug Disposition, 27, 119-124. [15]Ni J B, Zhang J C, Cheng S P. 2007. Diagnosis and treatment of mequindox posining in pigs. Chinese Journal of Animal Husbandry and Veterinary Medicine, 8, 66. (in Chinese) [16]Nie M Q, Guo X Q. 2009. Diagnosis and treatment of mequindox posining in chickens. Technical Advisor for Animal Husbandry, 3, 58. (in Chinese) [17]Nielsen P, Gyrd-Hansen N. 1996. Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. Journal of Veterinary Pharmacology and Therapeutics, 19, 305-311. [18]Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement J P, Houin G. 1987. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. Journal of Pharmacokinetics and Biopharmaceutics, 15, 225-239. [19]Polli J E, Bigora S, Piscitelli D A, Straughn A B, Young D. 1996. ‘Pavlovian’ food effect on the enterohepatic recirculation of piroxicam. Biopharmaceutics & Drug Disposition, 17, 635- 641. [20]Riley S A, Sutcliffe F, Kim M, Kapas M, Rowland M, Turnberg L A. 1992. The influence of gastrointestinal transit on drug absorption in healthy volunteers. British Journal of Clinical Pharmacology, 34, 32-39. [21]Rolan P, Molnar V. 2006. Clinical pharmacokinetics. In: Griffin J P, O’Grady J, Wells F O, eds., The Textbook of Pharmaceutical Medicine. 5th ed. Blackwell Pub. Malden, MA. pp. 176-197. [22]Schulze J D R, Waddington W A, Ell P J, Parsons G E, Coffin M D, Basit A W. 2003. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharmaceutical Research, 20, 1984-1988. [23]Spilsbury M L A. 2010. Clinical reports of carbadox toxicity in Mexican swine farms. Research Journal of Biological Sciences, 5, 9-12. [24]Varum F J O, Merchant H A, Basit A W. 2010. Oral modifiedrelease formulations in motion: The relationship between gastrointestinal transit and drug absorption. International Journal of Pharmaceutics, 395, 26-36. [25]Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. 2005. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research, 22, 728-735. [26]Wilding I R, Davis S S, Hardy J G, Robertson C S, John V A, Powell M L, Leal M, Lloyd P, Walker S M. 1991. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers. British Journal of Clinical Pharmacology, 32, 573-579. [27]Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 6, 547-558. [28]Yin O Q, Tomlinson B, Chow A H, Chow M S. 2003. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clinical Pharmacokinetics, 42, 179-192. [29]Zhao R, Xia W, Wang Y. 1982. Antibacterial activity and toxicity of “MAQO” and “MCEQO”. Journal of Traditional Chinese Veterinary Medicine, 1, 52-54. (in Chinese) [30]Zhou H W, Shen J Q, Lu M, Liang W Q, Lin W, Zhao W H. 1992. Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits. Acta Pharmacologica Sinica, 13, 180- 182. (in Chinese) [31]Zou J J, Chen Q, Tang S S, Jin X, Chen K P, Zhang T, Xiao X L. 2009. Olaquindox-induced genotoxicity and oxidative DNA damage in human hepatoma G2 (HepG2) cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 676, 27-33. |
| No Suggested Reading articles found! |
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
